PKN3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16117323	1.00	1/20
Aew-541 (SCHEMBL29358691)	1.00	1/20
SCHEMBL5936200	0.87	1/20
SCHEMBL5936204	0.87	1/20
SCHEMBL5936235	0.87	1/20
SCHEMBL16127375	0.86	1/20
SCHEMBL16415445	0.85	1/20
SCHEMBL16421433	0.85	1/20
SCHEMBL5936262	0.84	1/20
SCHEMBL5936264	0.84	1/20
SCHEMBL5936382	0.84	1/20
SCHEMBL5936303	0.82	1/20
SCHEMBL5936306	0.82	1/20
SCHEMBL5936322	0.82	1/20
Sapanisertib (SCHEMBL7902875)	0.82	1/20
Sapanisertib (SCHEMBL29351459)	0.82	1/20
SCHEMBL16117324	0.80	1/20
SCHEMBL6220135	0.79	1/20
SCHEMBL6220223	0.79	1/20
SCHEMBL11345478	0.79	1/20

Clinical trials — most relevant to PKN3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
L-arginine Treatment in Mild Hypertension	PHASE4	UNKNOWN
Salt Loading and Thiazide Intervention Study	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis	EARLY_PHASE1	RECRUITING
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy	nan	COMPLETED
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)	nan	RECRUITING
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
ERASE - Impact of COVID-19 on Malaria Control	nan	UNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas	nan	NOT_YET_RECRUITING
Pediatric Cardiomyopathy Mutation Analysis	nan	RECRUITING
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM	nan	RECRUITING
Markers and Mechanisms of Vascular Disease in Type II Diabetes	nan	COMPLETED
Microvascular Dysfunction and the Development of Whole-body Insulin Resistance	nan	COMPLETED
Pyruvate Kinase Deficiency Epidemiological Study (PIECE)	nan	COMPLETED
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors	nan	UNKNOWN
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
Molecular Mechanisms of Exercise Benefits to Insulin Resistant People	nan	COMPLETED
A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD	nan	NOT_YET_RECRUITING
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PKN3 binder may also engage these)

Protein	Name	Similarity
Q8K045	—	1.000	Q8K045 →
PKN1	Serine/threonine-protein kinase N1	0.992	landscape →
P70268	—	0.990	P70268 →
A1A4I4	—	0.989	A1A4I4 →
Q63433	—	0.982	Q63433 →
Q8BTM9	—	0.981	Q8BTM9 →
Q8TDF6	—	0.980	Q8TDF6 →
Q61161	—	0.979	Q61161 →
MAP4K2	Mitogen-activated protein kinase kinase kinase kinase 2	0.979	landscape →
A2VDW6	—	0.979	A2VDW6 →
Q9BST9	—	0.979	Q9BST9 →
Q3UR97	—	0.978	Q3UR97 →
B1WBU5	—	0.978	B1WBU5 →
PLK3	Serine/threonine-protein kinase PLK3	0.977	landscape →
P08923	—	0.976	P08923 →
B2RYG7	—	0.976	B2RYG7 →
RNF31	E3 ubiquitin-protein ligase RNF31	0.976	landscape →
MAP3K6	Mitogen-activated protein kinase kinase kinase 6	0.976	landscape →
Q8VCM2	—	0.976	Q8VCM2 →
Q86WN1	—	0.975	Q86WN1 →
P0C5K1	—	0.975	P0C5K1 →
O60496	—	0.975	O60496 →
A4D2P6	—	0.975	A4D2P6 →
Q4FZD7	—	0.974	Q4FZD7 →
Q0QWG9	—	0.974	Q0QWG9 →
B2RUP2	—	0.974	B2RUP2 →
Q80XL1	—	0.974	Q80XL1 →
Q8R5I4	—	0.974	Q8R5I4 →
Q6F5E8	—	0.974	Q6F5E8 →
Q9WTR2	—	0.974	Q9WTR2 →